New Zealand markets closed
  • NZX 50

    12,609.88
    +12.07 (+0.10%)
     
  • NZD/USD

    0.6770
    +0.0014 (+0.21%)
     
  • ALL ORDS

    7,605.20
    +76.20 (+1.01%)
     
  • OIL

    71.06
    +1.57 (+2.26%)
     
  • GOLD

    1,783.80
    +4.30 (+0.24%)
     

Will Merck's COVID-19 Pill Sink Regeneron's and Eli Lilly's Antibody Therapy Sales?

·2-min read

Merck (NYSE: MRK) and its partner, Ridgeback Biotherapeutics, hope to soon win U.S. Emergency Use Authorization (EUA) for the first COVID-19 pill. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss the potential impact of Merck's pill on COVID-19 antibody therapies.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting